{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-006973","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.971786+00:00","generated_at":"2026-05-17T00:38:27.682995+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Corvus Pharms Q3 net loss $10.2M, cash $65.7M; soquelitinib trials advancing","bullets":["Net loss of $10.2M for Q3 2025, improved from $40.2M loss in Q3 2024 which included $32.8M non-cash warrant liability loss.","Cash, equivalents & marketable securities $65.7M as of Sept 30, 2025, up from $52.0M at Dec 31, 2024; funding expected into Q4 2026.","Completed enrollment in soquelitinib atopic dermatitis Phase 1 extension cohort 4 (200 mg BID, 8 weeks); data expected January 2026.","On track to initiate soquelitinib atopic dermatitis Phase 2 trial in early Q1 2026, targeting ~200 patients.","Phase 3 registrational trial of soquelitinib in relapsed/refractory PTCL enrolling; final Phase 1/1b results to be presented at ASH December 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-006973","json":"https://secwatch.observer/filing/0001171843-25-006973.json","markdown":"https://secwatch.observer/filing/0001171843-25-006973.md","text":"https://secwatch.observer/filing/0001171843-25-006973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184325006973/0001171843-25-006973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184325006973/f8k_110425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:38:27.682995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}